Why is NeuroPace stock plummeting 40% today?

NeuroPace (NPCE) stock fell 38.3% to $7.42 after reporting Q3 2026 revenue of $23.1M, missing estimates of $27.1M. The company cut its full-year 2026 revenue outlook to $91–92M from $99.5–101.5M, citing sales force disruptions. Leerink downgraded NPCE to Market Perform with a $7 target, while KeyBanc reduced its target to $14. Insider selling and a rate-sensitive macro environment added to the decline.

Original reporting
Published Nov 13, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NPCE
Bearish
high confidence
Mentioned
$NPCE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NPCEBearishHigh
01

Why it matters

The earnings miss and downgrade caused a sharp intraday drop, signaling heightened risk for the stock.

02

Market read

The stock's steep decline underscores the sensitivity of small‑cap med‑tech names to earnings surprises.

03

What to watch

Potential upcoming clinical milestones could mitigate short‑term pain.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

NeuroPace reported Q3 2026 results, missing revenue estimates and cutting full‑year guidance.

Company-level read

Ticker impact

$NPCEBearishHigh confidence
Context

Q3 2026 revenue miss and full-year guidance cut triggered a 38% pre‑open plunge.

Expected impact

likely pressure as the market prices in the guidance reduction and analyst downgrade

Evidence & confidence

The earnings miss, guidance cut, and downgrade are fresh, material facts for a micro‑cap growth name.

Market effects

Highlights weakness in the neuro‑technology sector and may weigh on similar small‑cap med‑tech stocks.

Limited to U.S. markets; broader indices rose modestly, offering little offset.

Minimal global impact beyond niche investors.

Counterpoint

If the company can stabilize sales force execution, the price may be oversold.

Key entities

  • NeuroPace

    Developer of responsive neurostimulation devices.

  • Leerink

    Downgraded NPCE to Market Perform with a $7 target.

  • KeyBanc

    Trimmed price target to $14 while keeping Overweight.

Related articles

$NPCEMed

NeuroPace (NPCE) Q3 2026 Earnings Call Transcript

NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.

$NPCEMed

What NeuroPace (NPCE) Said on Its Q3 Earnings Call

NeuroPace (NPCE) reduced its 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing delays at large accounts. Q4 procedure volumes show recovery signs. Adjusted gross margin forecast raised to 83%-83.5%, while operating expenses lowered to $85M-$86M. 2027 RNS revenue growth expected at 15%. FDA submissions for IGE and Remote Care feature are planned.

$NPCEMed

NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i